Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Pfizer Inc. is conducting a study titled Real World Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy Against RSV Illness in Infants. The study aims to evaluate the effectiveness and impact of the ABRYSVO vaccine when administered during pregnancy, focusing on its ability to protect infants from RSV-related illnesses. This research is significant as it addresses a critical health concern for infants, potentially reducing hospitalizations and severe respiratory outcomes.
Intervention/Treatment: The intervention being tested is the ABRYSVO vaccine, a bivalent RSV prefusion F protein-based vaccine designed to protect against both RSV-A and RSV-B. The vaccine is administered to pregnant individuals to assess its protective effects on their infants.
Study Design: This observational study uses a retrospective case-control model. It involves three design approaches: a test negative design to evaluate vaccine effectiveness, a descriptive cohort design to analyze clinical outcomes in hospitalized infants, and an ecologic before-and-after design to assess the broader impact of the vaccination program.
Study Timeline: The study began on August 26, 2024, with primary completion expected in the subsequent RSV seasons. The last update was submitted on July 8, 2025. These dates mark the progression and ongoing nature of the study, providing a timeline for data collection and analysis.
Market Implications: The ongoing study could influence Pfizer’s stock performance positively if the results demonstrate significant vaccine effectiveness, potentially increasing investor confidence. The study’s outcome may also impact competitors in the RSV vaccine market, highlighting Pfizer’s role in advancing maternal and infant health solutions.
The study is currently active and not recruiting, with further details available on the ClinicalTrials portal.